Clinical significance micrometastatic disease in the era of sentinel node

Breast Disease

Volumn 12, Issue , 2001, Pages 57-67

  Ollila, D W ^a   Carey, L A ^a   Sartor, C I ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE; TISSUE SECTION; VALIDATION PROCESS;

EID: 0034852878     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2001-12107     Document Type: Article

References (65)

1. Intraoperative lymphatic mapping and selective lymphadenectomy: Technical details of a new procedure for clinical stage I melanoma
2. Technical details of intraoperative lymphatic mapping for early stage melanoma
3. Lymphatic mapping and sentinel lymphadenectomy for breast cancer
4. Gamma-probe guided localization of lymph nodes
5. The role of selective lymphadenectomy in the management of patients with malignant melanoma
6. Minimal-access surgery for staging of malignant melanoma
7. The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma
8. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma
9. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe
10. The sentinel node in breast cancer--a multicenter validation study
11. Localizing the sentinel node in cutaneous melanoma: Gamma probe detection versus blue dye
12. Intraoperative lymphatic mapping for early-stage malanoma of the head and neck
13. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer
14. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes
15. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma
16. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: A multicenter study
17. Sentinel lymphadenectomy: Immunohistologic validation and improved axillary staging for breast carcinoma: The Chapel Hill experience
18. Occult axillary lymph node metastases in invasive breast carcinoma: Characteristics of the primary tumor and significance of the metastases
19. Importance of tumor cells in axillary node sinus margins ("clandestine metastases") discovered by serial sectioning in operable breast carcinoma
20. Prognostic importance of occult axillary lymph node micrometastases from breast cancers
21. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Reevaluation with longer follow-up
22. Detection and significance of occult metastases in node-negative breast cancer
23. Occult axillary node metastases in breast cancer: Their detection and prognostic significance
24. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
25. Significance of occult metastases: A study of breast cancer
26. Immunohistology of the skin: Melanoma, intermediate filament
27. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma
28. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: A preliminary study
29. Serial sectioning of sentinel nodes in patients with breast cancer: A pilot study
30. Axillary sentinel lymph node examination in breast carcinoma
31. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients
32. Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node
33. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging
34. Improved axillary staging of breast cancer with sentinel lymphadenectomy
35. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients
36. Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up
37. Factors associated with regional nodal failure in patients with early stage breast cancer with 0-3 positive axillary nodes following tangential irradiation alone
38. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group
39. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation
40. Defining the role of post-mastectomy radiotherapy: The new evidence
41. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer
42. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma
43. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
44. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
45. Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined
46. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?
47. Sentinel lymph node biopsy with metastasis: Can axillary dissection be avoided in some patients with breast cancer?
48. Pathologic findings from the national surgical adjuvant breast project. (Protocol no. 4). III. The significance of extranodal extension of axillary metastases
49. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer
50. Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy
51. Microscopic extracapsular extension in the axilla: Is this an indication for axillary radiotherapy?
52. Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: An indication for radiotherapy?
53. The role of regional nodal irradiation in the management of patients with early-stage breast cancer treated with breast-conserving therapy
54. Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation
55. Sentinel node metastasis with extracapsular extension can predict risk of nonsentinel node involvement in breast cancer patients (poster presentation)
56. Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer
57. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast
58. Incidence and time of occurrence of regional recurrence in stage I-II breast cancer: Value of adjuvant irradiation
59. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation
60. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy
61. Axillary node micrometastases and breast cancer
62. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19
63. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification
64. Significance of axillary nodal micro- and macrometastases
65. Pathologic analysis of the sentinel lymph node